Michelot et al., 1991 - Google Patents
Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanomaMichelot et al., 1991
View PDF- Document ID
- 10048517239281058900
- Author
- Michelot J
- Moreau M
- Labarre P
- Madelmont J
- Veyre A
- Papon J
- Parry D
- Bonafous J
- Boire J
- Desplanches G
- Bertrand S
- Meyniel G
- Publication year
- Publication venue
- Journal of Nuclear Medicine
External Links
Snippet
The synthesis, labeling, and biodistribution of four 1251 radiopharmaceuticals designed to localize in melanoma were tested. Uptake in tumors was demonstrated by autoradiography of whole-body sections and quantitated by measurement of radioactivity of selected tissues …
- 201000001441 melanoma 0 title abstract description 70
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Michelot et al. | Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma | |
| US6096874A (en) | High affinity tamoxifen derivatives | |
| Garg et al. | Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity | |
| JP2022502422A (en) | Pharmaceutical agents for labeling inhibitors of prostate-specific membrane antigen (PSMA), their use as imaging agents, and treatment of PSMA-expressing cancers | |
| Wang et al. | Evaluation of F-18-labeled amino acid derivatives and [18F] FDG as PET probes in a brain tumor-bearing animal model | |
| Ren et al. | Melanin-targeted preclinical PET imaging of melanoma metastasis | |
| Otto et al. | Radioiodinated fatty acids for myocardial imaging: effects of chain length | |
| WO2012161177A1 (en) | Labeled derivative for image diagnosis of tumor | |
| Herman et al. | The use of pentafluorophenyl derivatives for the 18F labelling of proteins | |
| Lipowska et al. | Al18F-NODA-butyric acid: biological evaluation of a new PET renal radiotracer | |
| Yang et al. | Synthesis of [18F] fluoroalanine and [18F] fluorotamoxifen for imaging breast tumors | |
| Shi et al. | [68Ga] Ga-HBED-CC-DiAsp: A new renal function imaging agent | |
| CA2665494C (en) | Weakly basic 2-nitroimidazoles for the non-invasive detection of tissue hypoxia | |
| Zeng et al. | Synthesis and evaluation of [18F]-fluoromethyl triphenylphosphonium cation as a novel mitochondria-specific positron emission tomography tracer | |
| KR101130737B1 (en) | Radioactive cell labeling agent | |
| US4925651A (en) | Radiofluoro-tyrosine derivatives, the preparation and use thereof | |
| Yang et al. | Synthesis and biological evaluation of 99mTc-DMP-NGA as a novel hepatic asialoglycoprotein receptor imaging agent | |
| US20230277699A1 (en) | Tumor stroma imaging agent and preparation method thereof | |
| CN107847617A (en) | Metal tricarbonyl compound containing substituted iminodiacetic acid part and the purposes as radioisotopic tracer | |
| CN103275188B (en) | Radio-labeling T140 class polypeptide compound and its preparation method and application | |
| Moresco et al. | Synthesis and in vivo evaluation of [11C] ICI 118551 as a putative subtype selective β2-adrenergic radioligand | |
| Moon et al. | Synthesis of O-(3-[18F] fluoropropyl)-L-tyrosine (L-[18F] FPT) and its biological evaluation in 9L tumor bearing rat | |
| Edreira et al. | Iodide benzamides for the in-vivo detection of melanoma and metastases | |
| Ram et al. | Synthesis and biodistribution of peptide based 99mTc/186Re-MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts | |
| Saji et al. | Radioiodinated nordiazepam analog for in vivo assessment of benzodiazepine receptors by single photon emission tomography |